Investment firm Deep Track Capital, specializing in biotechnology, is once again drawing market attention. The firm is now actively competing for a seat on the board of directors of Dynavax Technologies $DVAX. Its primary focus is to ensure that new board directors prioritize the development of the company’s hepatitis B vaccine, signaling a strategic shift in management.